Arcus Biosciences Total Assets 2017-2021 | RCUS

Arcus Biosciences total assets from 2017 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Arcus Biosciences Annual Total Assets
(Millions of US $)
2020 $772
2019 $203
2018 $275
2017 $190
2016 $0
Arcus Biosciences Quarterly Total Assets
(Millions of US $)
2021-09-30 $839
2021-06-30 $899
2021-03-31 $935
2020-12-31 $772
2020-09-30 $811
2020-06-30 $481
2020-03-31 $176
2019-12-31 $203
2019-09-30 $217
2019-06-30 $239
2019-03-31 $259
2018-12-31 $275
2018-09-30 $287
2018-06-30 $294
2018-03-31 $305
2017-12-31 $190
2017-09-30 $0
2017-06-30 $0
2017-03-31 $0
2016-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.516B $0.078B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69